Address :
Hidoc Dr. Inc. | Delaware C Corp | 1309 Coffeen Ave. Suite 1200, Sheridan WY, 82801
Phone :
+1-415-463-3094
Email :
anishagadia@hidoc.co
Published Date: 17 Feb 2023
United States: The USPSTF advised against serological testing for the genital herpes simplex virus (HSV) in an advisory...
Read Full NewsA study of nearly 1 million veterans suggests that simpler lung cancer screening eligibility — based on smoking duration — would sharply reduce missed cancers and narrow disparities.
A large population study of young Black women aged 50 years or younger with invasive breast cancer highlights the importance of genetic testing in this population.
Eligible men with early prostate cancer can now be offered a high-precision radiotherapy technique on the NHS in England.
1.
High numbers of rural patients cross state lines for cancer care
2.
Even after a partial ban, asbestos is still used and is a deadly carcinogen, according to the EPA.
3.
Cancer Treatment Ups CV Risk; Therapy's Next Big Thing; Nude Photos Settlement
4.
Life quality after childhood cancer is quantifiable thanks to outcome indicators.
5.
Treating Depression: Crucial for Recovery From Fibromyalgia
1.
Navigating the Complexities of Melanoma Staging: A Comprehensive Guide
2.
Unexplained Weight Loss: Revealing Occult Cancers and Paraneoplastic Syndromes
3.
Macrocytic Anemia: A Comprehensive Review of Pathophysiology, Diagnosis, and Clinical Management
4.
Modern Techniques in Hematology Across Clinical Settings
5.
Overcoming Immunotherapy Resistance: Novel Checkpoints, Biomarkers, and Emerging Therapeutic Strategies
1.
Asian Symposium on Advancement in Hematology and Oncology
2.
International Cancer Conference
3.
Asian Symposium on Advancement in Hematology and Oncology
4.
Asian Symposium on Advancement in Hematology and Oncology
5.
International Lung Cancer Congress®
1.
Untangling The Best Treatment Approaches For ALK Positive Lung Cancer - Part III
2.
Treatment Sequencing Strategies in ALK + NSCLC Patients with CNS Diseases - Part II
3.
Revolutionizing Treatment of ALK Rearranged NSCLC with Lorlatinib - Part IV
4.
Redefining Treatment Pathways in Relapsed/Refractory Adult B-Cell ALL
5.
Navigating the Complexities of Ph Negative ALL - Part X
Address :
Hidoc Dr. Inc. | Delaware C Corp | 1309 Coffeen Ave. Suite 1200, Sheridan WY, 82801
Phone :
+1-415-463-3094
Email :
anishagadia@hidoc.co
© Copyright 2026 Hidoc Dr. Inc.
Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
To get started please enter your email ID
Join to enhance your clinical skills and gain specialized in-depth medical knowledge